U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H13N3.H3O4P
Molecular Weight 321.2683
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FADROZOLE PHOSPHATE, (R)-

SMILES

OP(O)(O)=O.[H][C@@]1(CCCC2=CN=CN12)C3=CC=C(C=C3)C#N

InChI

InChIKey=QPMXWEHWAGTWOC-PFEQFJNWSA-N
InChI=1S/C14H13N3.H3O4P/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14;1-5(2,3)4/h4-7,9-10,14H,1-3H2;(H3,1,2,3,4)/t14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H13N3
Molecular Weight 223.2731
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

(+)-Fadrozole (FAD-286) is an aldosterone synthase inhibitor. The drug was tested in vivo in preclinical models of hypertension, heart failure and was shown to reduce retinal neovascularization in rats with oxygen-induced retinopathy.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
3.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
In a preclinical study, (+)-fadrozole was given to rats at a dose of 30 mg/kg.
Route of Administration: Other
In Vitro Use Guide
(+)-Fadrozole inhibited angiotensin II-stimulated basal aldosterone production in NCI-H295R cells, showing a maximal effect at 10 nmol/l.
Substance Class Chemical
Record UNII
42REB33X4T
Record Status Validated (UNII)
Record Version